Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is on Fire Today

By George Budwell – May 18, 2020 at 9:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sorrento's shares are continuing their surge from last Friday. Here's why.

What happened

Sorrento Therapeutics (SRNE), a clinical-stage biotech, is off to a strong start this week. The drugmaker's shares are up by a healthy 42.6% in pre-market trading Monday morning. 

Last Friday, Sorrento's shares gained an astounding 158% in response to the company's announcement that it may have hit upon a highly effective preventative treatment for the novel coronavirus. This potential game-changer is an experimental antibody known as STI-1499. Today's double-digit move higher appears to be a continuation of last week's sizable rally. 

A researcher putting a liquid into a test tube.

Image source: Getty Images.

So what

Sorrento and partner Mount Sinai Health System are reportedly gearing up to evaluate STI-1499 as both a stand-alone therapy and part of an antibody cocktail designed to inhibit infection by the SARS-CoV-2 virus, which causes COVID-19. If successful, the antibody could be a big money-maker for the company. That's the good news. 

The bad news is that Sorrento is far from the only company developing an antibody regimen for COVID-19. Eli Lilly and Regeneron Pharmaceuticals, for instance, are both pursuing similar types of treatments for the respiratory disease.   

Now what

Is Sorrento's stock still worth buying on the heels of this news? While it can be tempting to chase high-flying biotech stocks on news, the smart play is arguably to remain on the sidelines. The market seems to be forecasting a major financial windfall for Sorrento, but that's far from a sure thing for a variety of reasons. Chief among them: Sorrento isn't even the front-runner in the race to develop an antibody against COVID-19.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics Stock Quote
Sorrento Therapeutics
SRNE
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
REGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.